Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Amgen Research (Munich) GmbH
Condition: Acute Lymphoblastic Leukemia
NCT00560794
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.